Pharmaceutical software specialist BioWisdom has launched a new version of its SRS system – a bioinformatics data integration platform, designed to meet the database search and retrieval needs of biologists and bioinformaticians.
The latest release, SRS version 8.3, provides new functionality, an improved user interface and support for the latest hardware and software platforms.
The system, which is used by pharmaceutical companies including GSK, Eli Lilly, Merck and Co, and Pfizer has been improved to include a new user annotations module, allowing users to add their own free text notes, and an alerting module to allow users to register their interests in specific queries.
Other developments include usability improvements, direct URL access and enhanced platform support.
BioWisdom’s CEO, Gordon Baxter, said: “This release is further demonstration of our continued commitment to SRS going forward. This latest version brings significant improvements to SRS customers and allows SRS to be at the centre of BioWisdom’s wider intelligent search capability. SRS is the search and integration capability that underpins BioWisdom’s Safety Intelligence Program.”
BioWisdom has also announced the availability of its SRS 3D technology, now free to users to download over the GNU operating system.
SRS 3D is a module of BioWisdom’s SRS system that enables the integration and display of sequences and annotations together with 3D structures.
Baxter added: “Making SRS 3D freely available as an open source, shortly after launching our OmniViz academic program, is a reflection of our continued commitment to supporting the work of the academic community. SRS users now have access to a leading tool for visualising protein structures in SRS.”
Link
Joe Fernandez